Abstract 2347P
Background
Many survivors of first primary cancers (FPCs) are at risk of developing a second primary cancer (SPC), the development of which usually leads to a worse prognosis. The development of SPCs may be closely related to the FPC. Different primary cancers have differentially high frequencies of specific SPC development. Our aim was to explore the possible correlation between the SPCs and FPCs.
Methods
We retrospectively searched and screened relevant literature on SPCs from four databases, namely, PubMed, EMBASE, Web of Science, and PMC. We also collected data on 28 different organ sites and the number of patients with SPC from The Surveillance, Epidemiology, and End Results (SEER) 8 Registry Database and NHANES database.
Results
A total of 9,617,643 patients with a FPC and 677,430 patients with a SPC were included in this meta-analysis. Patients with first primary gynaecological cancer and thyroid cancer developed second primary breast cancer and colorectal cancer more frequently. Patients with first primary head and neck cancer, anal cancer and esophageal cancer developed second primary lung cancer more frequently. Patients with first primary bladder cancer and penile cancer developed second primary lung cancer and prostate cancer more frequently. Patients with second primary bladder cancer accounted for 56% of first primary ureteral cancer patients with SPCs.
Conclusions
We recommend close clinical follow-up, monitoring and appropriate interventions in patients with relevant FPCs for better screening and early diagnosis of SPCs to prolong patient survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peng Luo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16